Current research efforts require a broad range of immune reagents; those available for pigs are limited. Our goal is to generate priority reagents, based on international input, and pipeline them for marketing. The UK partner will focus on mucosal targets, including production of monoclonal antibodies (mAbs) to chemokine receptors and IgE. US efforts are aimed at expression of soluble proteins and swine CD molecules, and production of panels of mAbs. The team has identified best immunization and screening strategies, set up collaborations with commercial partners for protein expression and mAb production, and updated protocols to evaluate reagent specificity. Our objectives are: 1) Clone and express swine cytokines and chemokines, IgE, CD antigens and receptors; 2) Prepare panels of mAbs reactive with swine targets; 3) Use reagents produced to develop new assays for swine immune markers, e.g., multiplex assays, intercellular staining, etc.; and 4) Provide the veterinary community with new commercial reagents and techniques for their research efforts. New panels of mAbs reactive with IL-6, IL-13, IFNβ and IFNγ are currently being evaluated. A mAb reactive with NK cell marker, NKp44 (NCR2, CD336), has been developed and characterized; however, using similar approaches mAbs reactive with NK cell marker, NKp30 (NCR3, CD337) and B cell marker, CD19 were not produced. Tools and reagents generated by this project will undoubtedly advance swine immune, disease and biomedical research efforts. Supported by USDA NIFA AFRI grants 2014-05989, 2010-65121-20649 and BBSRC grant BB/M028232/1.